Description of the medicine: Tiapride (Tiapride)
N- [2- (N, N-Diethylamino) ethyl] -2-methoxy-5- (methylsulfonyl) benzamide.
Synonyms: Delpral, Doparid, Mesulpridum, Tiapriazal, Tiapridal, Tiapridex, Tridal, etc.
Crystalline powder, white or white with a yellowish tint. Easily soluble in water, little in alcohol.
In structure and pharmacological properties, tiapride is close to sulpiride. It has an antidopaminergic effect.
It is used for hyperkinetic and dyskinetic disorders (chorea, nervous tics, senile psychomotor disturbances, trembling, etc.), headaches of neurogenic origin, reactive disorders of behavior, as well as psychomotor agitation and autonomic disorders in case of acute alcohol psychosis and withdrawal symptoms in patients alcoholism and drug addiction.
Assign inside and in the form of injections. Inside, it is taken for motor disorders at 0.3 - 0.6 g per day (in 2 to 3 doses), for reactive conditions with psychomotor agitation - at 0.6 - 1, 2 g per day, for alcoholism, headaches - 0.2 - 0.4 g per day. After achieving a therapeutic effect, the dose is reduced to 0.1 - 0.2 g per day.
Children aged 7 to 12 years with psychomotor imbalance or nerve tics are prescribed 0.05 g (1/2 tablet) 1 to 2 times a day.
For elderly patients, the drug is prescribed in a dose of 0.2 - 0.3 g per day, if necessary, the dose is slightly increased.
Intramuscularly, tiapride is administered to adults at 0.4 g (400 mg) per day.
If necessary, tiapride can be used in combination with antipsychotics, tranquilizers, antidepressants, analgesics and other neurotropic drugs.
Typically, tiapride is well tolerated. In some cases, drowsiness, seizures such as dyskinesia (convulsive movements of the eyeball, jaw compression) are observed. As a rule, these phenomena pass independently. If necessary, antiparkinsonian drugs are prescribed. In rare cases, amenorrhea, galactorrhea develop.
Method of production: 0.1 g tablets in a package of 20 pieces; 10% solution in ampoules of 2 ml (200 mg per ampoule) in a package of 12 ampoules.
Storage: List B.